Medical devices, healthcare technology and the business of care
PMA approval · P960043

PROSTAR 9 FR. PERCUTANEOUS VASCULAR SURGICAL (PVS) SYSTEM

Abbott Vascular, Inc. · Decision date Apr 30, 1997

MEDTECHLEDGER EXPLANATIONP960043

What did the FDA approve?

The FDA approved the PROSTAR 9 Fr. Percutaneous Vascular Surgical (PVS) System on April 30, 1997, under PMA number P960043. The system includes the PROSTAR PVS device in 9 and 11 French sizes, a pre-dilator in the same sizes, a Perclose knot pusher, a PROSTAR transition guidewire, and a Perclose arterial tamper.

According to the dated FDA statement, the system is indicated for percutaneous delivery of sutures to close the common femoral artery access site and reduce time to hemostasis and ambulation (time-to-standing) in patients who have undergone interventional procedures using 8 to 11 French sheaths. The statement does not include clinical data or independent proof of safety or effectiveness.

FDA approval order statement

APPROVAL FOR THE PROSTAR(R) PERCUTANEOUS VASCULAR SURGICAL (PVS) SYSTEM. THE PROSTAR(R) PVS SYSTEM CONSISTS OF THE PROSTAR(R) PVS DEVICE (9 AND 11 FRENCH SIZES) AND THE FOLLOWING ACCESSORIES: A PROSTAR(R) PRE-DILATOR (9 AND 11 FRENCH SIZES), A PERCLOSE(R) KNOT PUSHER, AND PROSTAR(R) TRANSITION GUIDEWIRE, AND A PERCLOSE(R) ARTERIAL TAMPER. THE PROSTAR(R) PVS SYSTEM IS INDICATED FOR THE PERCUTANEOUS DELIVERY OF SUTURES FOR CLOSING THE COMMON FEMORAL ARTERY ACCESS SITE ANC REDUCING THE TIME TO HEMOSTASIS AND AMBULATION (TIME-TO-STANDING) OF PATIENTS WHO HAVE UNDERGONE INTERVENTIONAL PROCEDURES USING 8 TO 11 FRENCH SHEATHS
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Apr 30, 1997

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P960043
Regulatory pathway
Premarket approval application
Product code
MGB
Decision code
APPR
Decision date
Apr 30, 1997
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, hemostasis, vascular.

Product code
MGB
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P960043 received

    Application receipt date recorded by FDA.

  2. P960043 · FDA decision

    APPR

  3. P960043/S137 · Related supplement

    Perclose ProGlide Suture-Mediated Closure System; Perclose ProStyle Suture-Mediated Closure and Repair System

  4. P960043/S138 · Related supplement

    Perclose ProStyle Suture-Mediated Closure and Repair System

  5. P960043/S139 · Related supplement

    Perclose ProGlide Suture-Mediated Closure System; Perclose ProStyle Suture-Mediated Closure and Repair System

Timeline entries are records held by MedtechLedger for P960043. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P960043

Explore the linked device profile

Other records with product code MGB

Product / regulatory recordCompanyPathwayDecision dateSource
Vasorum, Ltd.PMA supplementOct 30, 2026FDA
Vivasure Medical , Ltd.PMA approvalOct 16, 2026FDA
Cardiva Medical, Inc.PMA supplementSep 10, 2026FDA
Vasorum, Ltd.PMA approvalJul 20, 2016FDA
Cardiva Medical, Inc.PMA approvalJan 31, 2013FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Vascular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
400 Saginaw Dr., Redwood, CA, 94063

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records